Abstract |
Twenty-six patients with advanced breast cancer and progressive disease were treated by norethisterone. Estradiol and progesterone receptors were measured before starting treatment, and in three cases after 2 to 4.75 months of therapy. Partial remissions (greater than 50% decrease of all lesions) or objective improvements (decrease of 20-50%) were obtained in 7 patients, with a mean duration of 6.7 months. Stabilization of the lesions (no change or decrease of less than 20% in the size of the target lesion) was observed in 7 patients. No clear-cut correlation was found between clinical response and presence in biopsies of estradiol and progesterone receptors. However, absence of response occurred more frequently if tumors did not contain progesterone receptors.
|
Authors | B Clavel, M F Pichon, C Pallud, E Milgrom |
Journal | European journal of cancer & clinical oncology
(Eur J Cancer Clin Oncol)
Vol. 18
Issue 9
Pg. 821-6
(Sep 1982)
ISSN: 0277-5379 [Print] England |
PMID | 6891328
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Receptors, Estradiol
- Receptors, Estrogen
- Receptors, Progesterone
- Estradiol
- Norethindrone
|
Topics |
- Adult
- Aged
- Breast Neoplasms
(analysis, drug therapy)
- Estradiol
(analysis)
- Female
- Humans
- Male
- Middle Aged
- Norethindrone
(therapeutic use)
- Receptors, Estradiol
- Receptors, Estrogen
(analysis, drug effects)
- Receptors, Progesterone
(analysis, drug effects)
|